Your Yourlocation: Home > Study the safety of tiotropium bromide(136310-93-5) delivery by Spiriva Respimat

A major study of the safety of an aerosol inhaler for chronic lung disease found that this nebulizer did not increase the risk of premature death in patients, a finding that was in sharp contrast to an earlier analysis published two years ago. The study tested the use of Boehringer Ingelheim (BI) new pulmonary infusion device Respimat delivery of the company's a tiotropium bromide(136310-93-5)(Spiriva) preparations, the results of Boehringer Ingelheim and other products are being developed with LAMA competitive products Pharmaceutical manufacturers is undoubtedly good news.

The study, which included 17,135 patients, compared the safety and efficacy of Spiriva Respimat with the existing delivery device Handi Haler for the delivery of tiotropium bromide(136310-93-5). On September 8, the data were presented at the European Respiratory Society Conference in Barcelona was published.

A competitor in the field is GlaxoSmithKline, whose test drug, Anoro, consists of a LAMA drug and another different class of LABA drugs. The FDA advisory panel will be available to the FDA on September 10. This product is evaluated.

Industry analysts believe that Spiriva Respimat encouraging safety information may reduce regulatory barriers to new products containing LAMA. Some pharmaceutical manufacturers assert that LABA / LAMA inhalation devices will become the primary choice for chronic obstructive pulmonary disease (COPD). COPD causes people to breathe weakly and rapidly. More than 200 million people worldwide are affected by the disease.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved